



LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary) PTO FORM 1449	ATTY. DOCKET NO.	APPLICATION NO.
	05033.0006.PCUS00	10/511,108
	APPLICANT	
	RIDDER, R., et al.,	
	FILING DATE	GROUP
	October 8, 2004	1642

U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CH	1.	US 2003/0157482	08-2003	Keese et al.			
CH	2.	US 6,033,847	03-2000	Sherr et al.			
CH	3.	US 6,316,208	11-2001	Roberts et al.			
FOREIGN PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	4.						
	5.						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
	6.						
	7.						
	8.						
	9.						
	10.						
	11.						
	12.						
	13.						
	14.						
	15.						

Center June 4/30/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**LIST OF REFERENCES CITED BY APPLICANT**

(Use several sheets if necessary)

PTO FORM 1449

ATTY. DOCKET NO.

05033.0006.PCUS00

APPLICATION NO.

10/511,108

APPLICANT

RIDDER, R., et al.,

FILING DATE

October 8, 2004

GROUP

1642

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CJ	1.	US 4,281,061	07-1981	Zuk et al.,			
	2.						
	3.						

FOREIGN PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CJ	4.							
	5.							

OTHER REFERENCES

(Including Author, Title, Date, Pertinent Pages, Etc.)

	6.	He, et al., "Expression, Deletion And Mutation of p16 Gene in Human Gastric Cancer" <i>World J. of Gastroenterology</i> <u>7</u> (4): 515-521 (2001)
	7.	Myung, et al., "Loss Of p16 And p27 Is Associated With Progression Of Human Gastric Cancer" <i>Cancer Letters</i> <u>153</u> :129-136 (2000)
	8.	Nakao et al., "Induction of p16 During Immortalization HPV 16 and 18 and Not During Malignant Transformation" <i>British J of Cancer</i> <u>75</u> (10):1410-1416, 1997
	9.	O'Nions, et al., "p73 Is Over-Expressed In Vulval Cancer Principally As The Δ2 Isoform" <i>British J. Cancer</i> <u>85</u> (10):1551-1556 (Nov 2001)
	10.	Sano, et al., "Overexpression Of P16 And P14ARF Is Associated With Human Papillomavirus Infection In Cervical Squamous Cell Carcinoma And Dysplasia" <i>Pathology Int.</i> <u>52</u> :375-383 (May 2002)
	11.	Sherr, "The Ink4a/Arf Network In Tumor Suppression" <i>Nature Reviews Mol. Cell Bio</i> <u>2</u> :731-737, (2001)
	12.	Takeuchi, et al., "Altered p16/MTS1/CDKN2 and Cycling D1/PRAD-1 Gene Expression Is Associated With The Prognosis of Squamous Cell Carcinoma of the Esophagus" <i>Clinical Cancer Research</i> <u>3</u> :2229-2236, (1997)
	13.	Tsujiie, et al., "Expression of Tumor Suppressor Gene p16INK4 Products in Primary Gastric Cancer" <i>Oncology</i> <u>58</u> :126-136 (2000)
	14.	
	15.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DT04 Rec 31 CT/PTO 0 8 OCT 2004

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/511108
Filing Date	October 8, 2004
First Named Inventor	RIDDER, Ruediger
Art Unit	
Examiner Name	
Attorney Docket Number	05033.0006.PCUS00

Sheet 1 of 1

U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
CJ		US- 2002 106685 A1	08-08-2002	BAYER AG	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ³
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
CJ		WO 02 08764 A	01-31-2002	DOORBAR, JOHN		
		EP 1 217 377 A	06-26-2002	BAYER AG		
		WO 00 01845 A	01-13-2000	VON KNEBEL D.	whole document	

Examiner Signature	Cathleen Durr	Date Considered	4/30/07
-----------------------	---------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/511108
		Filing Date	October 8, 2004
		First Named Inventor	RIDDER, Ruediger
		Art Unit	
		Examiner Name	
Sheet 1	of 1	Attorney Docket Number	05033.0006.PCUS00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CJ	1	SANO T ET AL: "Expression status of p16...", American Journal of Pathology, Philadelphia, PA, US, vol. 153, no.6, 1998-12, pages 1741-1748	
	2	RIETHDORF S ET AL: "Analysis of p16/MTS1...", Virchows Archiv, vol. 439, no. 3, 2001-09, page 338	
	3	MILDE-LANGOSCH Karin et al: "Expression of cyclin-dependent kinase inhibitors...", Virchows Archiv, vol. 439, no.1, 2001-07, pages 55-61	
	4	KONNO R ET AL: "Detection of human papillomavirus DNA...", Tohoku Journal of Experimental Medicine, Japan, vol. 168, no. 3, 1992-11, pages 491-497	
	5	CHOO K B ET AL: "Integration of human papillomavirus type 16...", Virology, US, vol. 161, no. 1, 1987-11, pages 259-261. <i>Abstract</i>	
	6	NINDL I ET AL: "Human papillomavirus distribution in cervical tissues...", Int. Journal of Gynecological Pathology, New York, NY, US, vol. 16, no. 3, 1997, pages 197-204	
	7	KLAES RUEDIGER ET AL: "Overexpression of p16INK4a as a specific marker...", International Journal of Cancer, vol 92, no. 2, 2001, pages 276-284	
	8	WIEST Tina et al: "Involvement of intact HPV16 E6/E7 gene expression...", Oncogene, vol. 21, no. 10, 2002-02, pages 1510-1517. <i>Abstract</i>	
✓	9	SDEK Patima et al: "Influence of HPV16 on expression of RB...", Chinese Journal of Stomatology, China, vol. 37, no.2, 2002-03, pages 84-86. <i>Abstract</i>	

Examiner Signature	<i>Cathleen Dwyer</i>	Date Considered	4/30/07
--------------------	-----------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.